Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Palisade Bio, Inc. (NASDAQ:PALI) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.20.

A number of equities analysts have recently issued reports on PALI shares. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright assumed coverage on shares of Palisade Bio in a report on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective on the stock. Wolfe Research assumed coverage on shares of Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price objective on the stock.

Palisade Bio Trading Up 2.9%

Shares of PALI stock opened at $2.12 on Friday. The business’s fifty day simple moving average is $2.00 and its 200-day simple moving average is $1.93. The company has a market cap of $367.99 million, a PE ratio of -2.10 and a beta of 1.52. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities analysts forecast that Palisade Bio will post -0.21 earnings per share for the current year.

Institutional Investors Weigh In On Palisade Bio

Large investors have recently made changes to their positions in the stock. Cetera Investment Advisers purchased a new stake in shares of Palisade Bio during the fourth quarter valued at $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Palisade Bio during the fourth quarter valued at $26,000. Virtu Financial LLC purchased a new stake in shares of Palisade Bio during the fourth quarter valued at $28,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of Palisade Bio during the first quarter valued at $31,000. Finally, Atom Investors LP purchased a new stake in shares of Palisade Bio during the fourth quarter valued at $33,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.